Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples